1. Home
  2. SNDL vs DMAC Comparison

SNDL vs DMAC Comparison

Compare SNDL & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SNDL Inc.

SNDL

SNDL Inc.

HOLD

Current Price

$2.24

Market Cap

432.6M

Sector

Health Care

ML Signal

HOLD

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$9.40

Market Cap

457.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNDL
DMAC
Founded
2006
2000
Country
Canada
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
432.6M
457.2M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
SNDL
DMAC
Price
$2.24
$9.40
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$5.00
$15.50
AVG Volume (30 Days)
2.8M
581.8K
Earning Date
11-04-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$683,170,243.00
N/A
Revenue This Year
$5.48
N/A
Revenue Next Year
$3.10
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.43
N/A
52 Week Low
$1.15
$3.19
52 Week High
$2.89
$10.42

Technical Indicators

Market Signals
Indicator
SNDL
DMAC
Relative Strength Index (RSI) 70.31 69.32
Support Level $1.66 $7.76
Resistance Level $1.75 $10.42
Average True Range (ATR) 0.08 0.71
MACD 0.06 0.09
Stochastic Oscillator 94.26 64.37

Price Performance

Historical Comparison
SNDL
DMAC

About SNDL SNDL Inc.

SNDL Inc is a private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. The principal activities of the company are the retailing of wines, beers, and spirits. It comprised four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments. Liquor retail includes the sale of wines, beers, and spirits through owned liquor stores. The company generates maximum revenue from liquor retail.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: